The UltiFstack

What Is The Ultistack?

The Ultistack is Riptide Health's signature triple-peptide blend for visceral fat reduction, metabolic optimisation, and body recomposition research. It combines three compounds with complementary, non-overlapping mechanisms — each targeting fat metabolism and GH-axis regulation from a distinct biological angle — to produce a synergistic effect that exceeds what any single peptide can achieve alone.

Ultistack Composition (per 15mg vial):

Three equal parts. Three distinct pathways. One coordinated metabolic signal.

---

How The Three Components Work Together

AOD-9604 — Fat Mobilisation

AOD-9604 is a fragment of the human growth hormone molecule (amino acids 177–191), engineered to isolate HGH's fat-metabolising properties without raising IGF-1 or disrupting insulin regulation. It activates beta-3 adrenergic receptors in adipose tissue, directly stimulating lipolysis (breakdown of stored fat) and inhibiting lipogenesis (formation of new fat cells). Its action is peripheral and targeted — working at the fat cell level rather than through hormonal cascade.

Tesamorelin — GH Axis & Visceral Fat Targeting

Tesamorelin is a synthetic GHRH analogue — the only GHRH peptide with full FDA approval (for HIV-associated lipodystrophy). It stimulates the pituitary to release natural GH in a pulsatile, physiological pattern, which in turn elevates IGF-1 and drives preferential lipolysis in visceral adipose tissue (the intra-abdominal fat most strongly associated with metabolic disease risk). Clinical trials by Falutz et al. (NEJM, 2010) demonstrated statistically significant visceral fat reduction with sustained Tesamorelin use.

MOTS-c — Mitochondrial Metabolic Regulation

MOTS-c is a mitochondrially-encoded peptide that acts as an exercise-responsive metabolic signal — improving insulin sensitivity, glucose utilisation, and metabolic flexibility at the cellular level. By activating the AMPK pathway (the cell's energy sensor), MOTS-c improves the efficiency with which cells burn fat for energy, complements the GH-axis effects of Tesamorelin, and addresses the insulin-sensitising dimension of metabolic recomposition that neither AOD-9604 nor Tesamorelin directly targets.

Why These Three Together?

• AOD-9604 mobilises fat peripherally via adrenergic receptors
• Tesamorelin drives GH-mediated visceral fat reduction and lean mass preservation via the pituitary
• MOTS-c improves the metabolic environment at the mitochondrial level — making cells more responsive to the fat-burning signals the other two generate

Each peptide fills a gap the others leave. This is what makes The Ultistack genuinely synergistic rather than merely additive.

---

Research-Backed Benefits

Visceral Fat Reduction

The primary target. Tesamorelin has the strongest clinical evidence for visceral fat reduction of any peptide in this category — with imaging-confirmed VAT reduction in FDA-approved human trials. AOD-9604 adds a complementary adrenergic fat mobilisation mechanism, and MOTS-c improves the metabolic context in which fat is burned.

Improved Insulin Sensitivity & Metabolic Flexibility

MOTS-c's AMPK activation improves the cell's ability to respond to insulin and switch between glucose and fat as fuel sources — addressing one of the key metabolic impairments that makes visceral fat accumulation self-perpetuating.

Lean Mass Preservation

Tesamorelin's IGF-1 elevation maintains an anabolic environment that protects muscle tissue during caloric restriction — a critical feature for body recomposition protocols where the goal is adipose reduction without muscle sacrifice.

Mitochondrial & Metabolic Efficiency

MOTS-c's exercise-mimetic signalling improves overall metabolic function at the cellular level — relevant for both body composition and long-term metabolic health research.

Body Recomposition — The Bigger Picture

The Ultistack is designed for research into the intersection of visceral adiposity, growth hormone deficiency, and metabolic dysfunction — three conditions that are tightly correlated with ageing and that conventional approaches address only individually.

---

Dosing & Administration

Vial Contents: 15mg total (AOD-9604 5mg / Tesamorelin 5mg / MOTS-c 5mg) Route: Subcutaneous injection Typical Reconstitution: Add 2ml bacteriostatic water → yields 7.5mg/ml total

Understanding Component Concentrations (post-reconstitution at 2ml BAC)

Dose Calculation — Targeting Tesamorelin at 1.5mg/day: 1.5mg ÷ 2.5mg/ml = 0.6ml (60 IU on a U-100 syringe)

Dose Calculation — Targeting AOD-9604 at 0.5mg/day: 0.5mg ÷ 2.5mg/ml = 0.2ml (20 IU on a U-100 syringe)

Timing

• Evening subcutaneous injection is preferred — aligns with the natural nocturnal GH surge amplified by Tesamorelin
• Fasted state injection (minimum 2 hours post-meal) enhances GH release and fat mobilisation effects

Cycle

• 8–12 weeks per course
• Reassess metabolic markers (IGF-1, fasting glucose, body composition) at end of each cycle
• 4 week break recommended between cycles

Injection Sites: Abdomen, upper thigh, or glute — rotate with each injection

Reconstitution

• Add bacteriostatic water slowly down the vial wall — do not inject directly onto powder
• Swirl gently — never shake
• Refrigerate at 2–8°C and use within 28 days
• Discard if solution is cloudy or contains visible particles

---

Side Effects & Safety

The Ultistack's side effect profile reflects its three components individually. No unique interaction-specific adverse events have been identified.

Commonly reported

• Injection site redness or mild swelling — standard with any subcutaneous peptide; manage with site rotation
• Mild water retention in the first 1–2 weeks — related to Tesamorelin's GH elevation; typically self-limiting
• Mild joint or muscle aches — GH-related; dose-dependent and reversible
• Mild headache as GH and IGF-1 levels adjust — usually resolves within the first 2 weeks

Metabolic monitoring

• Tesamorelin can mildly impair glucose tolerance in some users — monitor fasting blood glucose during extended protocols, particularly if there is pre-existing insulin resistance
• IGF-1 should be checked at baseline and at 6–8 weeks — excessively elevated IGF-1 is associated with increased cancer risk and insulin resistance with prolonged exposure

Who should avoid or use with caution

• Cancer history — GH/IGF-1 elevation and angiogenic activity require oncology consultation before use
• Type 1 diabetes or insulin-dependent T2D — MOTS-c's insulin-sensitising effects could potentiate hypoglycaemia; close glucose monitoring and physician supervision required
• Pregnancy and breastfeeding — avoid use
• Pituitary disorders — consult an endocrinologist before using GHRH analogues

---

Who Is The Ultistack Best Suited For?

Research into visceral adiposity and metabolic syndrome

Individuals or researchers exploring the relationship between GH deficiency, insulin resistance, and visceral fat accumulation — where single-peptide approaches have not produced adequate outcomes.

Body recomposition protocols

Those seeking simultaneous adipose reduction and lean mass preservation — particularly individuals in the 35–60 age range where declining GH levels, reduced insulin sensitivity, and increasing visceral fat deposition are convergent challenges.

Post-hormonal optimisation support

Used as a metabolic and body composition support stack alongside other therapeutic protocols.